Orthofix Names Max Reinhardt President of Global Spine Business
May 23 2024 - 7:00AM
Business Wire
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and
orthopedics company, today announced the appointment of Max
Reinhardt as President of the Global Spine business effective June
10, 2024. Reinhardt will serve on the Executive Leadership Team and
be responsible for leading SeaSpine, the Company’s global spine and
biologics business.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240523192754/en/
Max Reinhardt, incoming President of the
Orthofix Global Spine business. (Photo: Business Wire)
Reinhardt’s experience spans more than 30 years in MedTech and
pharmaceuticals, assuming positions of increasing responsibility at
Johnson & Johnson, including serving as Worldwide President,
DePuy Synthes Spine, achieving the number two market share position
in the competitive spine market. Additionally, Reinhardt served as
Vice President, Marketing U.S. Orthopedics, and Global Franchise
Leader and Worldwide President of Joint Reconstruction, Sports
Medicine and Power Tools. Reinhardt has worked closely with key
opinion leaders and launched market-leading biologics and implant
solutions in spine surgery, joint replacement, orthopedic trauma
and early intervention, supported by a robust technique-based
professional education agenda.
“Max brings strong leadership and a proven track record of
success to our global spine business,” said Orthofix President and
CEO Massimo Calafiore. “He brings a wealth of experience in driving
innovation while continually executing focused strategies to drive
commercial success. I look forward to the guidance and expertise he
will bring to our organization as we continue to accelerate and
position Orthofix as one of the leading spine companies in the
market.”
Prior to his experience with Johnson & Johnson, Reinhardt
had senior leadership positions with Steris and Olympus in Europe.
Most recently, Reinhardt served in different leadership roles for
Pacira Biosciences, a company focused on providing innovative
non-opioid pain management solutions.
“I am delighted to have the opportunity to lead the talented
spine team at Orthofix as we continue to innovate and introduce
differentiated products and procedurally integrated solutions to
the market to solve complex spine problems,” said Reinhardt. “I
believe the company has a strong foundation and is well positioned
for growth in the years ahead. I look forward to working with our
dedicated team members to deliver new product solutions and provide
exceptional support for our surgeon customers and their
patients.”
Reinhardt earned his undergraduate diploma from Sparsholt
College, Hampshire, U.K. and a Master of Science degree from the
University of Hull, U.K.
About Orthofix
Orthofix is a leading global spine and orthopedics company with
a comprehensive portfolio of biologics, innovative spinal hardware,
bone growth therapies, specialized orthopedic solutions, and a
leading surgical navigation system. Its products are distributed in
more than 60 countries worldwide.
The Company is headquartered in Lewisville, Texas, where it
conducts general business, product development, medical education
and manufacturing, and has primary offices in Carlsbad, CA, with a
focus on spine and biologics product innovation and surgeon
education, and Verona, Italy, with an emphasis on product
innovation, production, and medical education for orthopedics. The
combined Company’s global R&D, commercial and manufacturing
footprint also includes facilities and offices in Irvine, CA,
Toronto, Canada, Sunnyvale, CA, Maidenhead, UK, Munich, Germany,
Paris, France and São Paulo, Brazil.
Forward-Looking Statements
This news release may include forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended, and Section 27A of the Securities Act of 1933, as
amended. In some cases, you can identify forward-looking statements
by terminology such as “may,” “will,” “should,” “expects,” “plans,”
“anticipates,” “believes,” “estimates,” “projects,” “intends,”
“predicts,” “potential,” “continue” or other comparable
terminology. Orthofix cautions you that statements included in this
news release that are not a description of historical facts are
forward-looking statements that are based on the Company’s current
expectations and assumptions. Each forward-looking statement
contained in this news release is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others: the ability of newly
launched products to perform as designed and intended and to meet
the needs of surgeons and patients, including as a result of the
lack of robust clinical validation; and the risks identified under
the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2023, which was
filed with the Securities and Exchange Commission (SEC) on March 5,
2024. The Company’s public filings with the Securities and Exchange
Commission are available at www.sec.gov. You are cautioned not to
place undue reliance on forward-looking statements, which speak
only as of the date when made. Orthofix does not intend to revise
or update any forward-looking statement set forth in this news
release to reflect events or circumstances arising after the date
hereof, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523192754/en/
Media Relations Denise Landry DeniseLandry@orthofix.com
214.937.2529 Investor Relations Louisa Smith, Gilmartin
Group IR@orthofix.com
Orthofix Medical (NASDAQ:OFIX)
Historical Stock Chart
From May 2024 to Jun 2024
Orthofix Medical (NASDAQ:OFIX)
Historical Stock Chart
From Jun 2023 to Jun 2024